Ductal lavage for early detection - What doesn't come out in the wash

Journal of the National Cancer Institute

Volumn 96, Issue 20, 2004, Pages 1488-1489

  Fabian, Carol J ^a   Kimler, Bruce F ^a   Mayo, Matthew S ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELECOXIB; ESTROGEN; GESTAGEN; PLACEBO;

ASPIRATION; ASPIRATION BIOPSY; BREAST CANCER; BREAST CELL; BREAST DISCHARGE; BREAST DUCT; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER TISSUE; CELL STRUCTURE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; EARLY DIAGNOSIS; ECHOMAMMOGRAPHY; EDITORIAL; FAMILY HISTORY; FEMALE; HORMONE SUBSTITUTION; HUMAN; LAVAGE; LIQUID; MASTECTOMY; NIPPLE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT CANCER; PAGET NIPPLE DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; ADULT; BREAST TUMOR; MAMMARY GLAND; NEEDLE BIOPSY; NOTE; PATHOLOGY; PREDICTION AND FORECASTING;

ADULT; BIOPSY, NEEDLE; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; EARLY DIAGNOSIS; FEMALE; HUMANS; IRRIGATION; MAMMARY GLANDS, HUMAN; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT;

EID: 6944237279     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh316     Document Type: Editorial

References (25)

1. Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002;359:909-19.
2. Cancer Facts & Figures 2004. Atlanta (GA): American Cancer Society; 2004. p. 9. Available at: http://www.cancer.org/downloads/STT/CAFF2004PWSecured.pdf. [Last accessed: September 17, 2004.]
3. Hendrick RE, Smith RA, Rutledge JH 3rd, Smart CR. Benefit of screening mammography in women aged 40-49: a new meta-analysis of randomized controlled trials. J Natl Cancer Inst Monogr 1997;(22):87-92.
4. Tabar L, Vitak B, Chen HH, Yen MF, Duffy SW, Smith RA. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer 2001;91:1724-31.
5. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:347-60.
6. Banks E, Reeves G, Beral V, Bull D, Crossley B, Simmonds M, et al. Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study. BMJ 2004;329:477.
7. Carney PA, Miglioretti DL, Yankaskas BC, Kerlikowske K, Rosenberg R, Rutter CM, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 2003;138:168-75.
8. Boyd NF, Jensen HM, Cooke G, Han HL. Relationship between mammographic and histological risk factors for breast cancer. J Natl Cancer Inst 1992;84:1170-9.
9. Ziv E, Shepherd J, Smith-Bindman R, Kerlikowske K. Mammographic breast density and family history of breast cancer. J Natl Cancer Inst 2003;95:556-8.
10. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-7.
11. Tilanus-Linthorst M, Verhoog L, Obdeijn IM, Bartels K, Menke-Pluymers M, Eggermont A, et al. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 2002;102:91-5.
12. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004;351:427-37.
13. Wrensch MR, Petrakis NL, King EB, Miike R, Mason L, Chew KL, et al. Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid. Am J Epidemiol 1992;135:130-41.
14. Wrensch MR, Petrakis NL, Miike R, King EB, Chew K, Neuhaus J, et al. Breast cancer risk in women with abnormal cytology in nipple aspirates of breast fluid. J Natl Cancer Inst 2001;93:1791-8.
15. Dooley WC, Ljung BM, Veronesi U, Cazzaniga M, Elledge RM, O'Shaughnessy JA, et al. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 2001;93:1624-32.
16. Sharma P, Klemp JR, Simonsen M, Welsko CM, Zalles CM, Kimler BF, Fabian CJ. Failure of high risk women to produce nipple aspirate fluid does not exclude detection of cytologic atypia in random periareolar fine needle aspiration specimens. Breast Cancer Res Treat 2004;87:59-64.
17. Khan SA, Baird C, Staradub VL, Morrow M. Ductal lavage and ductoscopy: the opportunities and the limitations. Clin Breast Cancer 2002;3:185-91.
18. Ljung BM, Chew KL, Moore DH 2nd, King EB. Cytology of ductal lavage fluid of the breast. Diagn Cytopathol 2004;30:143-50.
19. Khan SA, Wiley EL, Rodriguez N, Baird C, Ramakrishnan R, Nayar R, et al. Ductal lavage findings in women with known breast cancer undergoing mastectomy. J Natl Cancer Inst 2004;96:1510-8.
20. Sneige N, Staerkel GA. Fine-needle aspiration cytology of ductal hyperplasia with and without atypia and ductal carcinoma in situ. Hum Pathol 1994;25:485-92.
21. Sidawy MK, Stoler MH, Frable, WJ, Frost AR, Masood S, Miller TR, et al. Interobserver variability in the classification of proliferative breast lesions by fine-needle aspiration: results of the Papanicolaou Society of Cytopathology Study. Diagn Cytopathol 1998;18:150-65.
22. Masood S, Loya A, Khalbuss W. Is core needle biopsy superior to fine-needle aspiration biopsy in the diagnosis of papillary breast lesions? Diagn Cytopathol 2003;28:329-34.
23. Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Kamel S, Zeiger S, et al. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 2000;92: 1217-27.
24. Fabian CJ, Kimler BF, Brady DA, Mayo MS, Chang CH, Ferraro JA, et al. A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res 2002;8:3105-17.
25. Fabian CJ, Kimler BF, Mayo MS, Grizzle WE, Masood S, Ursin G. Clinical approaches to the discovery and testing of new breast cancer prevention drugs. In: Kelloff GJ, Hawk ET, Sigman CC, editors. Cancer chemoprevention. Vol 2. Strategies for cancer chemoprevention. Totowa (NJ): Humana Press. In press 2004.